Patents Assigned to DCB-USA LLC
-
Patent number: 11202854Abstract: Disclosed herein are disintegrin variants, and methods for suppressing or inhibiting platelet aggregation in a subject in need thereof. The method includes administering to the subject in need thereof an effective amount of the present disintegrin variant to alleviate or ameliorate symptoms associated with diseases, disorders, and/or conditions resulted from platelet aggregation. According to preferred embodiments, the present disintegrin variant is applied as a coating on an implantable device, such as a stent or a catheter.Type: GrantFiled: August 9, 2017Date of Patent: December 21, 2021Assignees: NATIONAL TAIWAN UNIVERSITY, NATIONAL CHENG KUNG UNIVERSITY, DCB-USA LLCInventors: Tur-Fu Huang, Yu-Ju Kuo, Woei-Jer Chuang
-
Patent number: 11142567Abstract: Disclosed herein is an anti-DENV antibody, a pharmaceutical composition comprising the same, and uses thereof. According to embodiments of the present disclosure, the anti-DENV antibody comprises a heavy chain variable region and a light chain variable region, in which the heavy chain variable region comprises amino acid sequences of SEQ ID NOs: 1-3, and the light chain variable region comprises amino acid sequences of SEQ ID NOs: 5-7.Type: GrantFiled: May 22, 2018Date of Patent: October 12, 2021Assignees: NATIONAL CHENG KUNG UNIVERSITY, DCB-USA LLCInventors: Trai-Ming Yeh, Yung-Chun Chuang, Yen-Chung Lai
-
Publication number: 20200164114Abstract: Disclosed herein are disintegrin variants, and methods for suppressing or inhibiting platelet aggregation in a subject in need thereof. The method includes administering to the subject in need thereof an effective amount of the present disintegrin variant to alleviate or ameliorate symptoms associated with diseases, disorders, and/or conditions resulted from platelet aggregation. According to preferred embodiments, the present disintegrin variant is applied as a coating on an implantable device, such as a stent or a catheter.Type: ApplicationFiled: August 9, 2017Publication date: May 28, 2020Applicants: National Taiwan University, NATIONAL CHENG KUNG UNIVERSITY, DCB-USA LLCInventors: Tur-Fu HUANG, Yu-Ju KUO, Woei-Jer CHUANG
-
Patent number: 10633453Abstract: Disclosed herein is a hinge antibody capable of being selectively activated in a target cell or tissue to treat a condition therein. The hinge antibody includes a functional antibody, two inhibitory domains and four cleavable linkers. The functional antibody is capable of treating the condition in an activated state, and has two light chains and two heavy chains. Each inhibitory domain includes a hinge domain of an immunoglobulin and consists of two peptide arms. Each cleavable linker includes a peptide substrate cleavable by an enzyme specifically or highly expressed in the target cell or tissue, and connects one of the peptide arms of the inhibitory domains to the N-terminal of one of the light chains and heavy chains of the functional antibody. Also disclosed herein are methods for preparing and using this hinge antibody.Type: GrantFiled: May 28, 2014Date of Patent: April 28, 2020Assignees: KAOHSIUNG MEDICAL UNIVERSITY, DCB-USA LLCInventors: Tian-Lu Cheng, Chih-Hung Chuang, Hsiu-Fen Ko, Yun-Chi Lu
-
Publication number: 20200087383Abstract: Disclosed herein is an anti-DENV antibody, a pharmaceutical composition comprising the same, and uses thereof. According to embodiments of the present disclosure, the anti-DENV antibody comprises a heavy chain variable region and a light chain variable region, in which the heavy chain variable region comprises amino acid sequences of SEQ ID NOs: 1-3, and the light chain variable region comprises amino acid sequences of SEQ ID NOs: 5-7.Type: ApplicationFiled: May 22, 2018Publication date: March 19, 2020Applicants: NATIONAL CHENG KUNG UNIVERSITY, DCB-USA LLCInventors: Trai-Ming YEH, Yung-Chun CHUANG, Yen-Chung LAI
-
Publication number: 20190284141Abstract: Disclosed is hydroxamic acid compounds of Formula (I) set forth herein. Also disclosed are a pharmaceutical composition containing such a compound and a method of using the compound for treating a condition associated with histone deacetylase 6.Type: ApplicationFiled: May 16, 2017Publication date: September 19, 2019Applicant: DCB-USA LLCInventors: Che-Ming TENG, Jing-Ping LIOU, Shiow-Lin PAN, Chia-Ron YANG
-
Publication number: 20190060382Abstract: The present invention provides a process for the preparation of a Crassocephalum crepidioides extract, and the extract prepared thereby. The present invention further relates to a pharmaceutical composition/combination comprising the Crassocephalum crepidioides extract. The use of the extract and the composition/combination comprising the extract in the prevention or treatment of cancer is also provided.Type: ApplicationFiled: December 31, 2015Publication date: February 28, 2019Applicants: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, DCB-USA LLCInventors: Dai-Hua TSAI, Tzung Hsien LAI, Tsui Hsu CHAN, Yuh Shan CHUNG, Li-Chuan HSU
-
Publication number: 20180208561Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein kinases.Type: ApplicationFiled: June 15, 2015Publication date: July 26, 2018Applicants: Development Center for Biotechnology, DCB-USA LLCInventors: Nan-Horng Lin, Chu-Bin Liao, Shao-Zheng Peng, Shih-Chieh Yen, Mann-Yan Kuo
-
Publication number: 20170369525Abstract: A method for specific linkage to a glycoprotein includes obtaining a glycoprotein having a monoglycan or diglycan attached thereto; producing a reactive functional group on a sugar unit on the glycoprotein; and coupling a linker or a payload to the reactive functional group on the glycoprotein.Type: ApplicationFiled: December 31, 2015Publication date: December 28, 2017Applicants: Development Center for Biotechnology, DCB-USA LLCInventors: Chao-Pin Lee, Cheng-Chou Yu, Chi-Huey Wong, Chuan-Lung Hsu, Chun-Chung Lee, Shih-Hsien Chuang, Ta-Tung Yuan, Yi-Jen Chen, Yu-Chin Nieh
-
Patent number: 9527922Abstract: A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.Type: GrantFiled: December 31, 2014Date of Patent: December 27, 2016Assignees: Development Center for Biotechnology, DCB-USA LLC, National Health Research InstitutesInventors: Shih-Chong Tsai, Ta-Tung Yuan, Shih-Chi Tseng, Jiann-Shiun Lai, Chia-Cheng Wu, Chao-Yang Huang, Ya-Wei Tsai, Ying-Yung Lok, Chung-Hsiun Wu, Neng-Yao Shih, Ko-Jiunn Liu, Li-Tzong Chen
-
Patent number: 9428575Abstract: An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.Type: GrantFiled: December 31, 2013Date of Patent: August 30, 2016Assignees: Development Center for Biotechnology, DCB-USA LLC, Academia SinicaInventors: Jiann-Shiun Lai, Hung-Ling Wang, Chao-Yang Huang, Ying-Yung Lok, Yuan-Tsong Chen, Woan-Eng Chan, Chih-Yung Hu
-
Publication number: 20160185875Abstract: Disclosed herein is a hinge antibody capable of being selectively activated in a target cell or tissue to treat a condition therein. The hinge antibody includes a functional antibody, two inhibitory domains and four cleavable linkers. The functional antibody is capable of treating the condition in an activated state, and has two light chains and two heavy chains. Each inhibitory domain includes a hinge domain of an immunoglobulin and consists of two peptide arms. Each cleavable linker includes a peptide substrate cleavable by an enzyme specifically or highly expressed in the target cell or tissue, and connects one of the peptide arms of the inhibitory domains to the N-terminal of one of the light chains and heavy chains of the functional antibody. Also disclosed herein are methods for preparing and using this hinge antibody.Type: ApplicationFiled: May 28, 2014Publication date: June 30, 2016Applicant: DCB-USA LLCInventors: Tian-Lu Cheng, Chih-Hung Chuang, Hsiu-Fen Ko, Yun-Chi Lu
-
Publication number: 20160185876Abstract: A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.Type: ApplicationFiled: December 31, 2014Publication date: June 30, 2016Applicants: Development Center for Biotechnology, DCB-USA LLC, National Health Research InstitutesInventors: Shih-Chong Tsai, Ta-Tung Yuan, Shih-Chi Tseng, Jiann-Shiun Lai, Chia-Cheng Wu, Chao-Yang Huang, Ya-Wei Tsai, Ying-Yung Lok, Chung-Hsiun Wu, Neng-Yao Shih, Ko-Jiunn Liu, Li-Tzong Chen
-
Publication number: 20160136176Abstract: The present invention relates to pyrimidine compounds of formula (I): which are useful in treating mTOR kinase- or PI3K kinase-related diseases.Type: ApplicationFiled: January 21, 2016Publication date: May 19, 2016Applicants: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, DCB-USA LLCInventors: Mann-Yan KUO, Ying-Shuan LEE, Paonien CHEN, Li Jung CHEN, Yann Yu LU, Yi-Ting HUANG, Hung-Yi HSU, Ping-Kuei TSAI
-
Publication number: 20160130336Abstract: An anti-VEGF antibody, or a binding fragment thereof, includes a heavy-chain variable region that comprises: (1) a CDRH1 sequence selected from SEQ ID NO: 17, 20, 23, 26, 29, 32, 35, or 38), (2) a CDRH2 sequence selected from SEQ ID NO:18, 21, 24, 27, 30, 33, 36, or 39, and (3) a CDRH3 sequence selected from SEQ ID NO:19, 22, 25, 28, 31, 34, 37, or 40; and a light-chain variable region that comprises: (1) a CDRL1 sequence selected from SEQ ID NO: 41, 44, 47, 50, 53, 56, 59, or 62, (2) a CDRL2 sequence selected from SEQ ID NO: 42, 45, 48, 51, 54, 57, 60, or 63, and (3) a CDRL3 sequence selected from SEQ ID NO: 43, 46, 49, 52, 55, 58, 61, or 64. A method for treating or preventing a VEGF-related disorder, e.g., diabetic retinopathy, age-related macular degeneration, or cancer, uses the antibodies.Type: ApplicationFiled: December 29, 2014Publication date: May 12, 2016Applicants: Development Center for Biotechnology, DCB-USA LLCInventors: Jiann-Shiun Lai, Yan-Da Lai, Yen-Yu Wu, Yi-Jiue Tsai, Yu-Ying Lin
-
Patent number: 9315491Abstract: The present invention relates to pyrimidine compounds of formula (I): which are useful in treating mTOR kinase- or PI3K kinase-related diseases.Type: GrantFiled: February 27, 2014Date of Patent: April 19, 2016Assignees: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, DCB-USA LLCInventors: Mann-Yan Kuo, Ying-Shuan Lee, Paonien Chen, Li Jung Chen, Yann Yu Lu, Yi-Ting Huang, Hung-Yi Hsu, Ping-Kuei Tsai
-
Publication number: 20160068595Abstract: A humanized antibody, or a scFv, Fab, or F(ab?)2 thereof, includes: a heavy chain variable region, or a homologous variant thereof, wherein the heavy chain variable region includes: heavy chain framework regions, CDRH1 that has the sequence of SEQ ID NO:19, CDRH2 that has the sequence of SEQ ID NO:20, and CDRH3 that has the sequence of SEQ ID NO:21, wherein the heavy chain variable region and the homologous variant share at least 90% sequence identity in the heavy chain framework regions; and a light chain variable region, or a homologous variant thereof, that includes: light chain framework regions, CDRL1 that has the sequence of SEQ ID NO:22, CDRL2 that has the sequences of SEQ ID NO:23, and CDRL3 that has the sequences of SEQ ID NO:24, wherein the light chain variable region and the homologous variant share at least 90% sequence identity in the light chain framework regions.Type: ApplicationFiled: April 18, 2014Publication date: March 10, 2016Applicants: Development Center for Biotechnology, DCB-USA LLCInventors: Chia-Cheng Wu, Chao-Yang Huang, Yu-Ying Lin, Yu-Jung Chen, Jiann-Shiun Lai
-
Patent number: 9216950Abstract: The present invention provides new compounds of formula I, II or III, which have Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1) agonist activity. Also provided are treatment methods using the compounds of formula I, II or III.Type: GrantFiled: August 3, 2012Date of Patent: December 22, 2015Assignees: NATIONAL TAIWAN UNIVERSITY, NATIONAL YANG-MING UNIVERSITY, DCB-USA LLCInventors: Chung-Wai Shiau, Kuen-Feng Chen
-
Publication number: 20150218251Abstract: The present invention provides isolated polypeptides comprising a modified fibronectin fragment that comprises FNIII 10 and optionally further comprising FNIII 9. Also provided are pharmaceutical compositions comprising the polypeptides and methods of making and using the polypeptides.Type: ApplicationFiled: June 7, 2013Publication date: August 6, 2015Applicants: NATIONAL CHENG KUNG UNIVERSITY, DCB-USA LLCInventors: Woei-Jer Chuang, Yung-Sheng Chang
-
Patent number: 9090617Abstract: The present invention provides new compounds of formula I, II or III, which have Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1) agonist activity. Also provided are treatment methods using the compounds of formula I, II or III.Type: GrantFiled: March 23, 2015Date of Patent: July 28, 2015Assignees: NATIONAL TAIWAN UNIVERSITY, NATIONAL YANG-MING UNIVERSITY, DCB-USA LLCInventors: Chung-Wai Shiau, Kuen-Feng Chen